Search

Your search keyword '"Huzarski T"' showing total 580 results

Search Constraints

Start Over You searched for: Author "Huzarski T" Remove constraint Author: "Huzarski T"
580 results on '"Huzarski T"'

Search Results

51. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers

52. Lynch syndrome mutations shared by the Baltic States and Poland

56. BRCA1-positive breast cancers in young women from Poland

58. Breast cancer predisposing alleles in Poland

59. CHEK2 is a multiorgan cancer susceptibility gene

60. 813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial

67. Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study)

68. A common variant of CDKN2A (p16) predisposes to breast cancer

71. Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States

73. Nuclear expression of Ku70/80 is associated with CHEK2 germline mutations in breast cancer

74. Meeting abstracts from the Annual Conference on Hereditary Cancers 2016

75. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

76. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study

77. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

78. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival

79. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

80. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

81. A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

82. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations

83. Meeting abstracts from the Annual Conference on Hereditary Cancers 2015

84. Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)

85. OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer

86. ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer

87. Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)

88. NewEPCAMfounder deletion in Polish population

89. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study

90. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study

91. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

92. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

93. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

94. Adult body mass index and risk of ovarian cancer by subtype: A Mendelian randomization study

95. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

96. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

97. Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer

98. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

99. The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania

100. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

Catalog

Books, media, physical & digital resources